EECP OM-A-I

EECP OM-A-I is a non-invasive EECP therapy system developed to improve symptoms associated with cardiovascular and cerebrovascular ischemia. The device operates in synchronization with the heartbeat, supporting blood flow through controlled pressure applied to the lower extremities and aiming to increase perfusion to the heart, brain, and other vital organs.

What is EECP?

EECP is a treatment method based on the inflation and deflation of cuffs placed on the legs and lower body, synchronized with the cardiac cycle via ECG signals. The patient lies on a treatment bed, and the system helps direct blood from the lower extremities to the upper body during the relaxation phase of the heart.

When the heart enters the pumping phase again, the pressure in the cuffs is rapidly released, supporting easier blood ejection from the heart. This mechanism is described as an “external heart” effect that supports circulation.

Working Principle

EECP OM-A-I monitors the heart rhythm via ECG and synchronizes pressure application accordingly. Thus, blood flow is directed to target organs during the heart’s relaxation phase.

Sequential pressure applied to the calves, thighs, and hips transports blood to the upper body, aiming particularly to increase perfusion to the heart and brain.

This process supports circulation by increasing blood flow to the heart, brain, kidneys, and other vital organs.

Indications and Areas of Use

EECP OM-A-I is primarily used to improve symptoms related to coronary artery disease. It provides a supportive approach in conditions such as stable and refractory angina, myocardial ischemia, and insufficient coronary perfusion.

It may also be used as supportive therapy in patients who cannot tolerate stent procedures or to reduce the risk of restenosis after revascularization.

In the cerebrovascular field, it can be used during rehabilitation after ischemic stroke, aiming to improve cerebral perfusion and support the development of collateral circulation.

Clinical Effects

EECP OM-A-I may help reduce angina symptoms and improve exercise tolerance by increasing coronary blood flow.

By enhancing myocardial perfusion, it supports reducing cardiac energy consumption and may contribute to collateral vessel formation.

It may help reduce the frequency of chest pain episodes and the use of nitroglycerin. It may also support functional improvement in patients with heart failure and ischemic cardiomyopathy.

Neurologically, it may increase cerebral perfusion, support collateral circulation, and improve neurological functions. Positive effects on quality of life have also been reported in some patients.

Mechanism of Action

EECP OM-A-I increases blood flow to the upper body during diastole, supporting perfusion of vital organs. This hemodynamic effect is important for both cardiac and cerebral circulation.

The increased blood flow creates shear stress on vessel walls, supporting endothelial function and improving vascular responses.

By affecting systemic circulation, it aims to improve peripheral vascular function and exercise capacity.

Clinical Benefits

EECP OM-A-I may contribute to reducing symptoms, increasing exercise capacity, and improving quality of life in patients with stable and refractory angina.

In ischemic stroke patients, it aims to improve cerebral hemodynamics, support motor and cognitive functions, and enhance overall quality of life.

Positive effects on psychological well-being, such as reduced anxiety and depression levels, have also been reported in some patients.

Product Features

EECP OM-A-I features an 18-inch LCD touchscreen that displays treatment data in real time and offers a user-friendly interface.

It provides stable and powerful performance with a compressor system of German origin and ensures comfortable use with low-noise operation.

An optional AF mode is available for patients with atrial fibrillation.

The device includes safety systems such as power failure protection, high-pressure protection, and manual pressure release.

A patient database allows easy recording and follow-up.

Technical Specifications

EECP OM-A-I supports 1:1 and 1:2 triggering ratios, with the 1:2 mode suitable for patients with higher heart rates.

The pressure range is specified as 50–350 mmHg.

An AF mode option is available for patients with atrial fibrillation.

Certification

The text states that EECP OM-A-I has SFDA, CE, and US FDA 510K certifications. It is recommended to verify these certifications according to the specific model and version.

General Overview

EECP OM-A-I is positioned as a non-invasive, circulation-supporting therapy system synchronized with the heartbeat. It aims to increase blood perfusion in coronary artery disease, angina, and ischemic conditions, while also offering supportive use in cerebrovascular rehabilitation.

With its advanced user interface, low-noise operation, safety systems, and patient data management features, it provides a comprehensive solution for clinical use.